by on August 15, 2017. For personal use only. jnm.snmjournals.org Downloaded from 2 ABSTRACT Expression of claudin-4, a protein involved in tight junction complexes, is widely dysregulated in epithelial malignancies. Claudin-4 is overexpressed in a number of premalignant precursor lesions, including those of cancers of the breast, pancreas and prostate, and is associated with poor survival. A non-cytotoxic c-terminal fragment of Clostridium perfringens enterotoxin (cCPE) is a natural ligand for claudin-4. Here, we demonstrate whole-body quantitative SPECT imaging of preneoplastic breast cancer tissue using 111 In-labelled cCPE.
INTRODUCTION
Early detection of cancer greatly increases the chances for successful treatment and long-term survival, and early diagnosis of cancer by medical imaging is certainly the major contributor to a reduction in mortality for breast cancer over the last decade (http://www.who.int), (1) . Even though the ability to detect precancerous lesions would even further improve the facility for early intervention and improved patient outcome, to date, few effective imaging methods exist to detect precancerous lesions. Here, we propose that molecular imaging using SPECT of the increased expression of claudin-4 in pre-cancerous lesions of the breast has potential to improve early detection.
Claudin-4 is a 22 kDa member of the 27-member claudin protein family, and is a vital component in adherens and tight junction complexes (2) . They are widely dysregulated in epithelial malignancies (3) .
Claudin-4 expression can be used to distinguish certain types of cancers (4) , since it is overexpressed in a number of premalignant precursor lesions compared to normal tissue, including lesions in the pancreas (5), prostate (6) , lung (7), colon (8) , and breast (3, 9, 10) , where claudin-4 overexpression is associated with poor prognosis. The exact mechanistic role of claudin-4 during tumorigenesis, and its role in solid tumours remains to be elucidated (3) . Nevertheless, it can act as a valid clinical biomarker for early diagnosis, as laid out in a recent review by Kwon et al. on ovarian cancers (3) . Also, Neesse et al. explored the possibility of claudin-4 targeting using fluorescently labelled proteins as imaging biomarkers in pancreatic cancer (5) .
Imaging of claudin-4 has been shown by Neesse et al. to be an effective way to detect (pre-) cancerous lesions of the pancreas (5) . Clostridium perfringens enterotoxin (CPE), which causes the symptoms of a very common food poisoning, is a natural ligand for claudin-4 (11) . It is a single polypeptide of approximately 35 kDa in size, and is associated with type A food poisoning and such non-foodborne gastrointestinal diseases as antibiotic-associated diarrhoea and sporadic diarrhoea (12) . The CPE receptorbinding activity of full-length CPE (319aa) is restricted to the 30 C-terminal amino acids (13) . Recently, by on August 15, 2017. For personal use only. jnm.snmjournals.org Downloaded from site-directed mutagenesis revealed three Tyr residues, located at positions 306, 310 and 312 to be critical for receptor binding to claudin-4. Furthermore, competitive binding experiments showed that C-terminal CPE (cCPE, residues 184-319, 15 kDa) binds with 1:1 stoichiometry and submicromolar affinity to pure claudin-4. It's been shown that cCPE, is sufficient to bind claudin-4, but does not exert cytotoxicity since it lacks residues 80-106 necessary for membrane insertion and pore formation (14) .
Neesse et al. used a Cy5.5-labelled glutathione S-transferase (GST)-tagged version of cCPE (cCPE.GST, 41 kDa), and showed excellent uptake in claudin-4 expressing xenografts, as well as claudin-4 expressing pancreatic tumors in an engineered mouse model of KRAS-mutation induced pancreatic ductal adenocarcinoma (PDAC). Earlier, Cocco et al. showed similar results using a FITC-conjugated cCPE in models of ovarian cancer (15) . However, the direct clinical translation of optical imaging approaches is limited by penetration depth of light, which is less than a couple of millimetres. To overcome this obstacle, we have now labelled cCPE with the radionuclide 111 In which emits tissue-penetrating gamma rays that can be detected by non-invasive SPECT imaging.
Here, we present our results on 111 In-labelled cCPE.GST. We demonstrate the possibility of whole body, non-invasive imaging of claudin-4 expression in two models of breast cancer in mice. We further establish the possibility of early detection of pre-cancerous aplastic lesions in a mouse model of HER2-overexpressing breast adenocarcinoma.
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MATERIALS AND METHODS
A COOH-terminal fragment of CPE (aa184-319) linked to a GST fusion protein has previously been produced by P. Michl (5) . Purity was confirmed by SDS-PAGE gel (Supplementary Figure S1) . A detailed procedure is laid out in the supplementary data. Purified cCPE.GST or GST was conjugated to benzyl-DTPA to allow radiolabelling with 111 In, as previously described (16). A detailed procedure is laid out in the supplementary data.
MDA-MB-468, SQ20b, and HT1080 human cancer cells were obtained from ATCC. Cells were tested and authenticated by the provider, using short tandem repeat profiling. The length of time in culture of these cells was less than 6 months after retrieval from liquid nitrogen storage. Cells were cultured in 5%
CO 2 in DMEM cell culture medium (Sigma-Aldrich) supplemented with 10% fetal calf serum (Invitrogen), and penicillin/streptomycin, 100 units/mL (Invitrogen).
Aliquots of 210 5 MDA-MB-468, SQ20b, or HT1080 cells were seeded on coverslips and allowed to adhere overnight. To determine claudin-4 expression, and the ability of cCPE to bind, cells were washed twice with PBS, fixed for 10 min at room temperature with 4% paraformaldehyde (Sigma), blocked with 2% bovine serum albumin in phosphate buffered saline (PBS, pH 7.4) for 1 h, and incubated with mouse anti-claudin-4 antibodies (R&D systems, clone 382321, 1:400 dilution in blocking buffer) for 1 h at 37°C, and, following 3 washes, goat anti-mouse antibody (Invitrogen; 1:250 dilution) labeled with AlexaFluor594 for 1 h at 37°C, and mounted using Vectashield containing DAPI (Vector Laboratories).
Confocal images were acquired using a Zeiss 530 confocal microscope (Zeiss). Results were confirmed using Western blot on whole cell lysates derived from all three cell lines, staining with anti-claudin-4
antibodies.
To investigate binding of 111 In-cCPE.GST to claudin-4 receptors, aliquots of 2 x 10 5 MDA-MB-468, SQ20b or HT1080 cells growing in a 24-well plate in 500 μL of growth medium were exposed to 1-1000 radioactivity, and cells were lysed using 0.1 M NaOH, as previously described (17). Radioactivity in cytoplasmic and nuclear fractions was counted in a gammacounter. Binding affinity and the number of accessible binding sites were estimated by non-linear regression analysis with a one-site total binding model using the software package GraphPad Prism (Graphpad Software Inc). In order to study binding specificity, in some cases increasing amounts of cold, unlabelled cCPE.GST was added, to compete with the binding of 2 nM 111 In-cCPE.GST. IC50 values were calculated by non-linear regression with a onesite competition model with variable Hill slope using GraphPad Prism.
In Vivo Studies
All animal procedures were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and with local ethical committee approval. MDA-MB-468 or HT1080 xenografts were established in female athymic balb/c nu/nu mice (Harlan). 111 In-cCPE.GST or 111 In-GST (5 MBq, 5 µg) was injected intravenously, and SPECT and CT images were acquired using a nanoSPECT-CT scanner (Bioscan) at 3 and 24 hours post injection (p.i.). Volume of interest (VOI) analysis on SPECT images was performed using the Inveon Research Workplace software package (Siemens). After imaging, mice were sacrificed and selected tissues were removed, rinsed, blot dried, weighed, and the amount of 111 In in each tissue was measured using an automated gammacounter. Uptake was expressed as the percentage of the injected dose per gram of tissue (%ID/g). In-cCPE.GST or GST imaging was performed as described above in balb/neuT mice aged around 80 days, bearing aplastic lesions, or aged 120-140 days, bearing overt mammary tumors.
After imaging, sections (10 µm) were generated from snap-frozen tumour tissue harvested from xenografts and balb/neuT mice. Sections were stained with H&E to confirm histological status. Other sections were stained for claudin-4, using mouse anti-claudin-4 antibodies (R&D systems, clone 382321), and mounted using Vectashield containing DAPI to stain for nuclei. Images were acquired using confocal microscopy as described above.
Statistical Analyses
All statistical analyses and non-linear regression were performed using Graphpad Prism. 1 or 2-way ANOVA was used for multiple comparisons, with Tukey post-tests to calculate significance of differences between groups. All data were obtained in triplicate or more independent replicates. Results are reported and graphed as averages ± one standard deviation, unless stated otherwise.
RESULTS
Reaction of a four-fold excess of pSCN-Bn-DTPA with cCPE.GST or GST resulted in a conjugation yield of approximately 1 DTPA molecule per cCPE.GST or GST protein. 111 In radiolabelling yield, as determined by ITLC or G25 SEC was routinely >95% (Supplementary Figure S2) .
Expression of claudin-4 on MDA-MB-468 and SQ20b, but not on HT1080 cells, was confirmed by immunocytochemistry and Western blot on whole cell lysates ( Figure 1A Figure 2B ).
Internalisation analysis in MDA-MB-468, SQ20b, or HT1080 cells revealed that 111 In-cCPE.GST, but not negative HT1080 cells (Supplementary Figure S4A) . Figure S4A,B) .
SPECT/CT imaging of athymic balb/c mice carrying subcutaneous xenograft tumors revealed marked uptake of 111 In-cCPE.GST in MDA-MB-468 xenografts, but 111 In-GST uptake in MDA-MB-468 xenografts was significantly lower (6.72±0.18 vs. 3.88±1.00 %ID/g; P<0.0001). 111 In-cCPE.GST was taken up in HT1080 tumors at much reduced levels (2.36±1.25 %ID/g; P<0.0001) ( Figure 3A ).
Immunohistochemistry on sections obtained from tumor tissue showed claudin-4 overexpression in MDA-MB-468, but not in HT1080 xenografts ( Figure 3B ), with densitometry corroborating these results Figure 3C) . Relative claudin-4 signal was 8.2±1.5-fold higher in MDA-MB-468
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xenografts, compared to HT1080 tumors (P<0.0001). SPECT imaging results were confirmed by gamma counting of tumor tissues after dissection. 111 In-cCPE.GST uptake in MDA-MB-468 xenografts was 6.72 ± 0.18 %ID/g, 24 hours after injection, significantly higher than 111 In-GST (3.88 ± 1.00 %ID/g; P<0.0001), and uptake of 111 In-cCPE.GST in claudin-4 negative HT1080 xenografts (2.36 ± 1.16 %ID/g; P<0.0001) ( Figure 3C ). Uptake in normal tissues was limited, resulting in tumor-to-muscle and tumor-toblood ratios of 7.83±0.21 and 4.00±0.11, respectively, in MDA-MB-468 xenograft bearing mice, 24 h after injection of 111 In-cCPE.GST, significantly higher than 111 In-GST, or 111 In-cCPE.GST in HT1080 xenograft-bearing mice (tumor-to-muscle ratios of 4.53±1.17 and 2.98±1.57 and tumor-to-blood ratios 2.11±0.54 and 1.32±0.70, respectively; P<0.05; Figure 3C ). Uptake of 111 In was also observed in knee and shoulder joints, potentially a result from the use of DTPA as a chelator. Some limited uptake of 111 IncCPE.GST was observed in the intestines, especially the small intestine. It was also observed that uptake of 111 In-cCPE.GST in normal mammary fat pads in these animals is low (1.36±0.35 %ID/g).
Claudin-4 expression in established mammary tumors, harvested from 120-140 day-old balb/neuT mice was confirmed using immunohistochemistry ( Figure 4A, Supplementary Figure S4D ). Claudin-4 signal from carcinomas was 3.1±0.7-fold higher compared to normal muscle tissue. Histological stage was confirmed using H&E and anti-SMA staining (Supplementary Figure S5A and B) . Established tumors, measuring 280 mm 3 on average, were clearly visualised with 111 In-cCPE.GST on SPECT/CT images ( Figure 4B ). Moreover, CT imaging could also visualise these tumors. Uptake of 111 In-cCPE.GST in tumor tissue in balb/neuT mice was significantly higher compared to 111 In-GST control (at 3 h post injection, uptake was 8.50±1.40 vs. 4.50±1.10 %ID/g, respectively; P<0.01) (Supplementary Figure 6A) . Given the well-known disadvantages associated with xenograft models (these disadvantages are reviewed in great detail elsewhere (22) detection almost 40% (50 days) earlier, in mice aged 80 days, and prior to CT imaging. Given that X-ray imaging is currently used as the preferred method of breast cancer screening, our method of very early detection may enable even earlier therapeutic intervention, or trigger more frequent follow-up of patients at risk. Here, we have described a SPECT imaging method for claudin-4 imaging, but since PET imaging has a much increased sensitivity compared to SPECT, and PET results can be more easily quantified, a translation of the SPECT imaging method described here to PET imaging using alternative radioisotopes 
